Back to Search
Start Over
DNA polymerase inhibitors for treating hepatitis B: a safety evaluation.
- Source :
-
Expert opinion on drug safety [Expert Opin Drug Saf] 2016; Vol. 15 (3), pp. 383-92. Date of Electronic Publication: 2016 Feb 01. - Publication Year :
- 2016
-
Abstract
- Introduction: Oral nucleoside/ nucleotide analogues (NAs) are currently the mainstay of treatment for patients with chronic hepatitis B virus (HBV) infection. They are generally safe to use. However, since their approval in the last decade and a half, the literature has reported adverse effects associated with the use of NA in HBV patients. A comprehensive review on the drug safety is lacking.<br />Areas Covered: Significant adverse effects associated with NA use in HBV patients including muscle toxicity, peripheral neuropathy, nephrotoxicity and lactic acidosis are discussed. The reported prevalence of each adverse effect, as well as their predictive factors, reversibility and their use in pregnancy and lactating mothers are covered in this review. Novel data regarding reno-protective effect of telbivudine are also discussed.<br />Expert Opinion: Use of NA in HBV is generally safe. Uncommon adverse effects can be minimized or detected early if clinicians exercise adequate precautions when using NA for at-risk populations with regular monitoring.
- Subjects :
- Animals
Antiviral Agents pharmacology
Antiviral Agents therapeutic use
Female
Humans
Lactation
Nucleic Acid Synthesis Inhibitors pharmacology
Nucleic Acid Synthesis Inhibitors therapeutic use
Pregnancy
Pregnancy Complications, Infectious drug therapy
Pregnancy Complications, Infectious virology
Antiviral Agents adverse effects
Hepatitis B, Chronic drug therapy
Nucleic Acid Synthesis Inhibitors adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 1744-764X
- Volume :
- 15
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Expert opinion on drug safety
- Publication Type :
- Academic Journal
- Accession number :
- 26752687
- Full Text :
- https://doi.org/10.1517/14740338.2016.1139573